| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Quercetin 7-glucuronide exerts its effects through several mechanisms, including antioxidant activity by scavenging free radicals and reducing oxidative stress. It inhibits LDL oxidation and exhibits anti-inflammatory effects by inhibiting the production of inflammatory cytokines and enzymes. It also has anti-tumor, anti-aging, and hepatoprotective activities.
|
|---|---|
| ln Vitro |
In vitro, quercetin 7-glucuronide inhibits LDL oxidation. Studies using HepG2 hepatic cells indicate that it can undergo methylation (approximately 44%) and hydrolysis (7%) to form various metabolites such as quercetin-3'-sulfate. It exhibits antioxidant, anti-inflammatory, and potential therapeutic properties.
|
| ln Vivo |
In vivo, quercetin 7-glucuronide is a metabolite of quercetin that is formed in the small intestine and further processed in the liver. It exerts its biological effects through antioxidant and anti-inflammatory mechanisms. Its metabolic transformations modulate its biological activity.
|
| Enzyme Assay |
In vitro enzyme assays for quercetin 7-glucuronide typically involve studying its formation and metabolism using enzymes such as UDP-glucuronosyltransferases (UGTs). UGTs catalyze the transfer of glucuronic acid from UDP-glucuronic acid to quercetin. The compound can also be studied using methyltransferases and beta-glucuronidase.
|
| Cell Assay |
For in vitro cell assays, cells such as HepG2 hepatic cells are cultured and treated with quercetin 7-glucuronide. Cellular uptake, methylation, and hydrolysis are analyzed by LC-MS. Anti-inflammatory effects are evaluated by measuring cytokine production. Antioxidant activity is assessed by measuring ROS levels and LDL oxidation inhibition.
|
| Animal Protocol |
For in vivo animal studies, quercetin 7-glucuronide is typically studied after oral administration of quercetin. Blood and tissue samples are collected, and the compound is quantified by LC-MS. Its formation, distribution, and metabolism are assessed. Its effects on oxidative stress and inflammation are evaluated in disease models.
|
| ADME/Pharmacokinetics |
Quercetin 7-glucuronide (MW 478.4 g/mol) has the molecular formula C₂₁H₁₈O₁₃. It is a solid compound that should be stored at 2-8°C protected from light. It is a flavonoid glycoside formed by the attachment of a glucuronic acid molecule to the quercetin molecule.
|
| Toxicity/Toxicokinetics |
The compound is for research use only. No specific toxicity data are available. As a natural metabolite of quercetin, it is expected to have low toxicity. Quercetin and its glucuronides are generally considered safe and are found in various fruits, vegetables, and grains.
|
| References | |
| Additional Infomation |
Quercetin 7-glucuronide (CAS# 38934-20-2) is a metabolite of the dietary flavonoid quercetin. It has not been approved as a therapeutic drug. The compound is used in research on antioxidant, anti-inflammatory, and anticancer activities. It is a valuable tool for studying flavonoid metabolism and the health benefits of dietary polyphenols.
|
| Molecular Formula |
C21H18O13
|
|---|---|
| Molecular Weight |
478.36
|
| Exact Mass |
478.075
|
| CAS # |
38934-20-2
|
| PubChem CID |
11641481
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
0.6
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
34
|
| Complexity |
830
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O)O)O)O
|
| InChi Key |
JXWGCVLNCGCZRU-JENRNSKYSA-N
|
| InChi Code |
InChI=1S/C21H18O13/c22-8-2-1-6(3-9(8)23)18-15(27)13(25)12-10(24)4-7(5-11(12)33-18)32-21-17(29)14(26)16(28)19(34-21)20(30)31/h1-5,14,16-17,19,21-24,26-29H,(H,30,31)/t14-,16-,17+,19-,21+/m0/s1
|
| Chemical Name |
(2S,3S,4S,5R,6S)-6-[2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4-oxochromen-7-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0905 mL | 10.4524 mL | 20.9048 mL | |
| 5 mM | 0.4181 mL | 2.0905 mL | 4.1810 mL | |
| 10 mM | 0.2090 mL | 1.0452 mL | 2.0905 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
